Steve Closter serves as the Chief Commercial Officer at Syndax Pharmaceuticals Inc., a position he has held since joining the company in 2021. In his role, Closter is responsible for overseeing the commercialization strategy and execution for Syndax's portfolio of innovative cancer therapies. His leadership has been instrumental in guiding the company through the complex landscape of oncology drug development and market entry. Prior to joining Syndax, Closter amassed over two decades of experience in the biopharmaceutical industry, with a strong focus on oncology and hematology. He held several senior leadership positions, including roles at Celgene Corporation, where he was instrumental in the successful launch and growth of multiple blockbuster oncology products. Closter's expertise in strategic planning, market access, and sales force effectiveness has been recognized throughout his career, earning him a reputation as a visionary leader in the field. At Syndax, Closter has been pivotal in shaping the company's commercial strategy, particularly as it relates to the development and potential launch of revumenib, a promising therapy for acute leukemias. His deep understanding of the oncology market, coupled with his ability to build and lead high-performing teams, has positioned Syndax for success as it transitions from a development-stage company to a commercial entity. Closter's contributions have been vital in advancing Syndax's mission to deliver transformative therapies to patients in need.